Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2025-12-25 @ 4:58 AM
NCT ID:
NCT07118618
Brief Summary:
This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.
Detailed Description:
There are three aims in this study that test the hypothesis that probenecid compared to placebo, decreases:
* Aim 1 (laboratory phase): acute alcohol craving.
* Aim 2 (naturalistic phase): alcohol craving.
* Aim 3 (naturalistic phase): alcohol consumption
Study:
NCT07118618
Study Brief:
Protocol Section:
NCT07118618